Therapies for COVID-19-Related Persistent Olfactory Disorders: One of the Good Fruits of the Pandemic.

Sven Saussez Luigi Angelo VairaGiacomo De RiuJérôme René Lechien

Published in: Pathogens (Basel, Switzerland) (2023)

At the beginning of 2021, the scientific community realized the burden of COVID-19-related persistent olfactory disorders (ODs). The percentage of those infected with COVID-19 who developed severe and persistent ODs [1-3] with devastating effects on their quality of life was 5 to 40% [4,5].

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus
healthcare
mental health
risk factors
early onset